doctor and patient

Trendlines Gets Grant for Urinary Incontinence Device

Trendlines Labs is to receive a grant from the Singapore Israel Industrial Research and Development Foundation for the development and clinical trial of its stress urinary incontinence (SUI) product, which is being developed in partnership with the Singapore General Hospital.  The 50 women in the trial, expected to start mid-2017 at the hospital, will provide feedback on the product. The foundation will provide up to 50 percent of the $400,000 the partners need to fund the final product development and clinical trial.  Trendlines Labs, the innovation arm of The Trendlines Group Ltd., the Israeli venture fund and tech accelerator firm, has developed a nonsurgical, non-pharmaceutical solution to mitigate SUI, a form of incontinence that affects approximately 15 million women in the US alone, according to the Women’s Health Foundation. SUI is caused by weak sphincter muscles or weak pelvic floors, and can occur when there is abdominal stress on the pelvic organs — the bladder, vagina, uterus, or rectum. Read more.

Source: Times of Israel, April 3, 2017

operating room

StimGuard Enrolls First Patient in Office-Based Chronic Tibial Nerve OAB Incontinence Stimulation Study Utilizing the World’s Smallest Wireless System

StimGuard, a privately-held, pre-commercial stage medical device company, today announced the initiation and the first patient enrollment in a clinical trial of the world’s first miniature implantable device for the treatment of urgency urinary incontinence resulting from refractory overactive bladder (OAB) syndrome. The StimGuard device utilizes wireless technology and is placed through an introducer device the size of a needle at the tibial nerve to activate the afferent micturition (neural urinary) pathways. The clinical trial of this novel approach will launch this winter. Read more.

Source: Business Wire, December 15, 2016

medical research

Cytori Pivotal ADRESU Incontinence Trial Hits 50% Enrollment Milestone

Cytori Therapeutics, Inc. (CYTX) today announced that over half of 45 patients in the ADRESU trial in Japan have been enrolled and treated. ADRESU is a late phase, investigator-initiated Japanese clinical trial to study the efficacy and safety of Cytori Cell TherapyTM in men with stress urinary incontinence after prostatic intervention for prostate cancer or benign prostatic hypertrophy. Read more.

Source: Yahoo! Finance, December 14, 2016